Payment overview · 2025
General Payments
$167.97
9 reported records · 8 companies
Healthcare provider profile · identity verified
Joseph Hans Kohn, ARNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ELMA, WA · NPI 1083141105
Verified facts
What the public records show
CMS Open Payments records show Joseph Hans Kohn, ARNP-C received $167.97 in general payments during 2025 across 9 reported records.
Novartis Pharmaceuticals Corporation accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.36 | 16.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.99 | 14.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.02 | 13.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.85 | 13.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.71 | 12.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.17 | 12.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.72 | 9.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.15 | 9.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $167.97 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.36 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.17 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 102 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
104 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 479 | 92 |
| Gabapentin | Gabapentin | 350 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 295 | 60 |
| Lisinopril | Lisinopril | 268 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 262 | 47 |
| Omeprazole | Omeprazole | 231 | 50 |
| Losartan Potassium | Losartan Potassium | 229 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 207 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 160 | 18 |
| Metformin Hcl | Metformin Hcl | 149 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 134 | 27 |
| Simvastatin | Simvastatin | 134 | 29 |
| Trazodone Hcl | Trazodone Hcl | 125 | 23 |
| Potassium Chloride | Potassium Chloride | 121 | 27 |
| Baclofen | Baclofen | 119 | 20 |
| Furosemide | Furosemide | 118 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 28 |
| Allopurinol | Allopurinol | 115 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 23 |
| Glipizide | Glipizide | 106 | 17 |
| Eliquis | Apixaban | 105 | 18 |
| Mounjaro | Tirzepatide | 104 | 14 |
| Jardiance | Empagliflozin | 102 | 22 |
| Metformin Hcl Er | Metformin Hcl | 96 | 17 |
| Warfarin Sodium | Warfarin Sodium | 93 | suppressed |
| Famotidine | Famotidine | 92 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 83 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 14 |
| Lamotrigine | Lamotrigine | 81 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 14 |
| Ozempic | Semaglutide | 78 | 16 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 77 | suppressed |
| Meloxicam | Meloxicam | 75 | 23 |
| Spironolactone | Spironolactone | 75 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 15 |
| Pregabalin | Pregabalin | 68 | 17 |
| Lovastatin | Lovastatin | 67 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 66 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 65 | 14 |
| Glipizide Er | Glipizide | 63 | 16 |
| Buspirone Hcl | Buspirone Hcl | 62 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 62 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 13 |
| Ibuprofen | Ibuprofen | 59 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 16 |
| Prednisone | Prednisone | 59 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | suppressed |
| Bupropion Xl | Bupropion Hcl | 54 | 13 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 16 |
| Carvedilol | Carvedilol | 48 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Alprazolam | Alprazolam | 46 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | suppressed |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Atenolol | Atenolol | 44 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 13 |
| Finasteride | Finasteride | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | 12 |
| Topiramate | Topiramate | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 14 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 18 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Celecoxib | Celecoxib | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Risperidone | Risperidone | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $167.97 · 9 records | Novartis Pharmaceuticals Corporation | Cologuard Collection Kit, JARDIANCE, LEQVIO, MAVYRET, NURTEC ODT, Ozempic, TRELEGY ELLIPTA, VOQUEZNA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error